Aktienanalyse zu Revelation Biosciences Inc (REVB)REVBRevelation Biosciences Inc

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Revelation Biosciences Inc is not a strong buy at the moment due to ongoing financial losses and volatility, despite a promising analyst target of $16. The current price is $1.05, with a year-to-date change of -67.72%. The main risk is the significant net loss of $59.76 million reported for FY 2025, which raises concerns about future profitability and funding needs.

1 analysts cover REVB: 1 rate it Buy, 0 Hold and 0 Sell.